publication . Article . 2012

Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe

Guo, Ning; Ma, Ying; Jacboson, Orit; Lee, Seulki; Niu, Gang; Chen, Xiaoyuan; Zhu, Lei; Li, Quanzheng; Choi, Hak Soo; Mansfield, James R.;
Open Access English
  • Published: 01 Aug 2012 Journal: Theranostics, volume 2, issue 8, pages 746-756 (eissn: 1838-7640, Copyright policy)
  • Publisher: Ivyspring International Publisher
Abstract
Purpose: The aim of this study is to determine if dynamic optical imaging could provide comparable kinetic parameters to that of dynamic PET imaging by a near-infrared dye/64Cu dual-labeled cyclic RGD peptide. Methods: The integrin αvβ3 binding RGD peptide was conjugated with a macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for copper labeling and PET imaging and a near-infrared dye ZW-1 for optical imaging. The in vitro biological activity of RGD-C(DOTA)-ZW-1 was characterized by cell staining and receptor binding assay. Sixty-min dynamic PET and optical imaging were acquired on a MDA-MB-435 tumor model. Singular value deco...
Subjects
free text keywords: integrin αvβ3, dual modality imaging, RGD peptide., Singular value decomposition (SVD), Research Paper, dynamic imaging, kinetic modeling
41 references, page 1 of 3

Cai, W, Rao, J, Gambhir, SS, Chen, X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006; 5: 2624-33 [PubMed]

Delbeke, D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40: 591-603 [PubMed]

Bomanji, JB, Costa, DC, Ell, PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001; 2: 157-64 [PubMed]

La Fougere, C, Suchorska, B, Bartenstein, P, Kreth, FW, Tonn, JC. Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol. 2011; 13: 806-19 [OpenAIRE] [PubMed]

Phelps, ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81 [PubMed]

Cai, W, Chen, X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 (Suppl 2): 113S-28S [PubMed]

Ye, Y, Chen, X. Integrin targeting for tumor optical imaging. Theranostics. 2011; 1: 102-26 [OpenAIRE] [PubMed]

Hoshi, Y. Functional near-infrared optical imaging: Utility and limitations in human brain mapping. Psychophysiology. 2003; 40: 511-20 [PubMed]

Shah, K, Weissleder, R. Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx. 2005; 2: 215-25 [OpenAIRE] [PubMed]

Ntziachristos, V, Bremer, C, Weissleder, R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-208 [PubMed]

Zhu, L, Niu, G, Fang, X, Chen, X. Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging. 2010; 54: 291-308 [OpenAIRE] [PubMed]

Niu, G, Chen, X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47 [OpenAIRE] [PubMed]

Carter, A. Integrins as target: First phase III trial launches, but questions remain. J Natl Cancer Inst. 2010; 102: 675-7 [PubMed]

Millard, M, Odde, S, Neamati, N. Integrin Targeted Therapeutics. Theranostics. 2011; 1: 154-188 [OpenAIRE] [PubMed]

Schottelius, M, Laufer, B, Kessler, H, Wester, HJ. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res. 2009; 42: 969-80 [PubMed]

41 references, page 1 of 3
Abstract
Purpose: The aim of this study is to determine if dynamic optical imaging could provide comparable kinetic parameters to that of dynamic PET imaging by a near-infrared dye/64Cu dual-labeled cyclic RGD peptide. Methods: The integrin αvβ3 binding RGD peptide was conjugated with a macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for copper labeling and PET imaging and a near-infrared dye ZW-1 for optical imaging. The in vitro biological activity of RGD-C(DOTA)-ZW-1 was characterized by cell staining and receptor binding assay. Sixty-min dynamic PET and optical imaging were acquired on a MDA-MB-435 tumor model. Singular value deco...
Subjects
free text keywords: integrin αvβ3, dual modality imaging, RGD peptide., Singular value decomposition (SVD), Research Paper, dynamic imaging, kinetic modeling
41 references, page 1 of 3

Cai, W, Rao, J, Gambhir, SS, Chen, X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006; 5: 2624-33 [PubMed]

Delbeke, D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40: 591-603 [PubMed]

Bomanji, JB, Costa, DC, Ell, PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001; 2: 157-64 [PubMed]

La Fougere, C, Suchorska, B, Bartenstein, P, Kreth, FW, Tonn, JC. Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol. 2011; 13: 806-19 [OpenAIRE] [PubMed]

Phelps, ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81 [PubMed]

Cai, W, Chen, X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 (Suppl 2): 113S-28S [PubMed]

Ye, Y, Chen, X. Integrin targeting for tumor optical imaging. Theranostics. 2011; 1: 102-26 [OpenAIRE] [PubMed]

Hoshi, Y. Functional near-infrared optical imaging: Utility and limitations in human brain mapping. Psychophysiology. 2003; 40: 511-20 [PubMed]

Shah, K, Weissleder, R. Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx. 2005; 2: 215-25 [OpenAIRE] [PubMed]

Ntziachristos, V, Bremer, C, Weissleder, R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-208 [PubMed]

Zhu, L, Niu, G, Fang, X, Chen, X. Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging. 2010; 54: 291-308 [OpenAIRE] [PubMed]

Niu, G, Chen, X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47 [OpenAIRE] [PubMed]

Carter, A. Integrins as target: First phase III trial launches, but questions remain. J Natl Cancer Inst. 2010; 102: 675-7 [PubMed]

Millard, M, Odde, S, Neamati, N. Integrin Targeted Therapeutics. Theranostics. 2011; 1: 154-188 [OpenAIRE] [PubMed]

Schottelius, M, Laufer, B, Kessler, H, Wester, HJ. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res. 2009; 42: 969-80 [PubMed]

41 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2012

Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe

Guo, Ning; Ma, Ying; Jacboson, Orit; Lee, Seulki; Niu, Gang; Chen, Xiaoyuan; Zhu, Lei; Li, Quanzheng; Choi, Hak Soo; Mansfield, James R.;